1-(2-(N,N-dimethylamino)ethyl)-6-(tetrahydropyran-4-yl)-1H-indazole | 281204-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(2-(N,N-dimethylamino)ethyl)-6-(tetrahydropyran-4-yl)-1H-indazole
• 英文别名: N,N-dimethyl-2-[6-(oxan-4-yl)indazol-1-yl]ethanamine
• CAS: 281204-15-7
• 化学式: C₁₆H₂₃N₃O
• 分子量: 273.378
• InChiKey: BEKPQAOCQGMOSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-碘四氢-2H-吡喃 、 6-bromo-1-(2-(N,N-dimethylamino)ethyl)-1H-indazole 生成 1-(2-(N,N-dimethylamino)ethyl)-6-(tetrahydropyran-4-yl)-1H-indazole
  参考文献：
  名称：

  N-alkylamino-indoles for the treatment of migraine

  摘要：

  本发明涉及一种具有通式（II）的化合物，用于治疗偏头痛。

  公开号：

  US06380242B1

文献信息

• [EN] INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE<br/>[FR] DERIVES INDOLE ET INDOLIZIDINE PERMETTANT DE TRAITER LES MIGRAINES
  申请人：ALLELIX BIOPHARMA

  公开号：WO2000038677A1

  公开（公告）日：2000-07-06

  Described herein are compounds useful in the treatment of migraine, which have general formula (I) wherein: X is selected from the group consisting of N, CH; R1 represents a 5- to 7-membered monocyclic or benzo-fused heterocyclic ring, which may be unsaturated, and which may contain one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino and mono- or di-lower alkyl amino; Ak represents a C1-3alkylene chain which may be substituted with R2, where R2 represents lower alkyl; R3 and R4 are independently selected from the group consisting of H, lower alkyl, lower alkenyl, cycloalkyl and optionally-substituted benzyl; or one pair of R2 and R3 or R3 and R4 together may form an alkylene or alkenylene bridge which, with the nitrogen atom, form a 3- to 7-membered ring which may contain one or more substituents selected from the group consisting of lower alkyl, hydroxy, hydroxymethyl, alkoxymethyl, amino and substituted amino; R5 is selected from the group consisting of H, lower alkyl and a 4- to 7-membered carbocyclic or heterocyclic group, which may be unsaturated; and a salt, solvate or prodrug thereof. Also disclosed are novel compounds of formula (II) wherein: X is selected from the group consisting of N and CH; R6 represents a 5- to 7-membered monocyclic or benzo-fused heterocyclic ring, which may be unsaturated, and which may contain one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino and mono- or di-lower alkyl amino; Ak represents a C1-3alkylene chain which may be substituted with R7, where R7 represents lower alkyl; R8 and R9 are independently selected from the group consisting of H, lower alkyl, lower alkenyl, cycloalkyl and optionally-substituted benzyl; R10 is selected from the group consisting of H, lower alkyl and a 4- to 7-membered carbocyclic or heterocyclic group, which may be unsaturated, and a salt, solvate or prodrug thereof.

  本文介绍了一些用于治疗偏头痛的化合物，其具有一般式 (I)，其中：X选自N，CH组成的群；R1表示一个5-至7-成员的单环或苯并螺环，可以不饱和，并且可以含有一个或多个取代基，所述取代基选自较低烷基，羟基，较低烷氧基，氨基和单个或双个较低烷基氨基；Ak表示可以用R2取代的C1-3烷基链，其中R2表示较低烷基；R3和R4独立地选自H，较低烷基，较低烯基，环烷基和可选取代的苄基；或者R2和R3或R3和R4中的一对可以一起形成烷基或烯基桥，与氮原子一起形成一个3-至7-成员的环，所述环可以含有一个或多个取代基，所述取代基选自较低烷基，羟基，羟甲基，烷氧甲基，氨基和取代氨基；R5选自H，较低烷基和一个4-至7-成员的碳环或杂环基，可以不饱和；以及其盐，溶剂化合物或前药。本文还公开了新的化合物，其具有式（II），其中：X选自N和CH组成的群；R6表示一个5-至7-成员的单环或苯并螺环，可以不饱和，并且可以含有一个或多个取代基，所述取代基选自较低烷基，羟基，较低烷氧基，氨基和单个或双个较低烷基氨基；Ak表示可以用R7取代的C1-3烷基链，其中R7表示较低烷基；R8和R9独立地选自H，较低烷基，较低烯基，环烷基和可选取代的苄基；R10选自H，较低烷基和一个4-至7-成员的碳环或杂环基，可以不饱和；以及其盐，溶剂化合物或前药。
• Use of N-alkylamino-heterocylic compounds for the treatment of migraine
  申请人：NPS Allexlix Corp.

  公开号：US20020169322A1

  公开（公告）日：2002-11-14

  Described are compounds having formula I or II: 1 wherein: X is N, CH or C-lower alkyl; R 1 represents a 5 to 7-membered monocyclic or benzo-fused heterocyclic ring, Ak represents a C 1-3 alkylene chain; R 3 and R 4 are H, lower alkyl, lower alkenyl or optionally-substituted benzyl; or one pair of R 2 , R 3 or R 3 , R 4 together may form an alkylene or alkenylene bridge which, with the nitrogen atom, form a 3- to 7-membered ring; R 5 is H, lower alkyl or a 4- to 7-membered carbocyclic or heterocyclic group; R 6 represents a 5 to 7-membered monocyclic or benzo-fused heterocyclic ring; R 8 and R 9 are H, lower alkyl, lower alkenyl or optionally-substituted benzyl; R 10 is H, lower alkyl or a 4- to 7-membered carbocyclic or heterocyclic group; and a salt, solvate or prodrug thereof.

  描述了具有公式I或II的化合物：1其中：X为N、CH或C-较低烷基；R1表示5至7成员的单环或苯并嵌杂环；Ak表示C1-3烷基链；R3和R4为H、较低烷基、较低烯基或可选取代苄基；或者R2、R3或R3、R4中的一对可以共同形成与氮原子一起形成3至7成员环的烷基或烯基桥；R5为H、较低烷基或4至7成员的碳环或杂环基团；R6表示5至7成员的单环或苯并嵌杂环；R8和R9为H、较低烷基、较低烯基或可选取代苄基；R10为H、较低烷基或4至7成员的碳环或杂环基团；以及其盐、溶剂化物或前药。
• INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
  申请人：NPS Allelix Corp.

  公开号：EP1140074A1

  公开（公告）日：2001-10-10
• US6380242B1
  申请人：——

  公开号：US6380242B1

  公开（公告）日：2002-04-30
• US6635639B2
  申请人：——

  公开号：US6635639B2

  公开（公告）日：2003-10-21